Regioselective addition of Grignard reagents to N-acylpyrazinium salts: synthesis of substituted 1,2-dihydropyrazines and Δ5-2-oxopiperazines

  1. 1 ,
  2. 1 ,
  3. 1 ,
  4. 1 ORCID Logo and
  5. 1,2 ORCID Logo
1Biomanufacturing Research Institute and Technology Enterprise (BRITE), North Carolina Central University, Durham, North Carolina 27707, United States
2Department of Pharmaceutical Sciences, North Carolina Central University, Durham, North Carolina 27707, United States
  1. Corresponding author email
Associate Editor: D. Y.-K. Chen
Beilstein J. Org. Chem. 2019, 15, 72–78. https://doi.org/10.3762/bjoc.15.8
Received 22 Sep 2018, Accepted 10 Dec 2018, Published 08 Jan 2019
Full Research Paper
cc by logo

Abstract

The regioselective addition of Grignard reagents to mono- and disubstituted N-acylpyrazinium salts affording substituted 1,2-dihydropyrazines in modest to excellent yields (45–100%) is described. Under acidic conditions, these 1,2-dihydropyrazines can be converted to substituted Δ5-2-oxopiperazines providing a simple and efficient approach towards their preparation.

Introduction

Pyrazine and piperazine ring systems are key structural elements in a large number of biologically active molecules [1-6]. Compounds containing these scaffolds were shown to behave as anticancer agents [2-5], sodium channel blockers [5], and also display antiviral activity [7]. Due to their appearance in an array of biologically active small molecules and natural products, efficient synthetic routes into this class of privileged structures would be very beneficial [7,8]. One approach towards their synthesis involves the addition of nucleophiles to activated pyrazines. We recently showed that 3-alkoxy-substituted N-acylpyrazinium salts can be selectively reduced by tributyltin hydride to afford 1,2-dihydropyrazines in good to excellent yields [9]. There have been other reports involving the addition of TMS-ketene acetals to pyrazinium salts [10-12]. A double nucleophilic addition of bis(trimethylsilyl)ketene acetals to pyrazines activated with methyl chloroformate was found to afford polycyclic γ-lactones in moderate yields [3,10,11]. The work by Garduño-Alva and co-workers demonstrated that these TMS-ketene acetals can be regioselectively added to substituted N-triflate pyrazinium salts to also generate γ-lactones [12].

Grignard reagents have been used as nucleophiles on a variety of N-acyl-activated pyridines in the production of natural products and biologically active small molecules [13-20]. To our surprise, there are no reports on the nucleophilic addition of Grignard reagents to N-acylpyrazinium salts. A literature search showed this organometallic reagent reacting with pyrazine N-oxides towards the one-pot synthesis of N-Boc-protected N-hydroxy-substituted piperazines in good yields [6]. Methylmagnesium iodide was observed adding to 2-cyano-6-morpholinylpyrazine [21]. As a part of our continued exploration into the synthetic utility of N-acylpyrazinium salts, herein we report the regioselective addition of Grignard reagents to mono- and disubstituted N-acylpyrazinium salts towards the synthesis of 1,2-dihydropyrazines and Δ5-2-oxopiperazines.

Results and Discussion

Our journey began by first reacting 2-methoxypyrazine with phenyl chloroformate to generate the N-acylpyrazinium salt 2 using DCM as the solvent. Next, phenylmagnesium bromide in THF was added at −41 °C. After stirring for 60 min, dihydropyrazine 3a was isolated in a yield of 40% (entry 1, Table 1). This initial low yield prompted us to switch the Grignard solvent from THF to DCM. Using modified reaction conditions from Andersson and co-wokers [22], phenylmagnesium bromide in DCM was added to 2 at −41 °C and after 35 min, dihydropyrazine 3a was only isolated in a 32% yield (entry 2, Table 1). The lower yields appear to be caused by the Grignard attacking the carbonyl of the N-acyl salt 2 causing the formation of phenyl benzoate. When toluene was used as the solvent, both 3a and the ester were obtained in yields of 41% and 39%, respectively (entry 3, Table 1). Changing the solvent to diethyl ether showed no improvement in the yield of 3a but when THF was used, an excellent yield of 87% was produced (entries 4 and 5, Table 1).

Table 1: Phenyl Grignard addition to methoxy-substituted N-acylpyrazinium salts.

[Graphic 1]
entrya solvent time (min) yield 3a (%)b
1 DCM 60 40
2c DCM 35 32
3 toluene 40 41d
4 diethyl ether 60 15
5 THF 30 87e

aGrignard reagent in THF. bIsolated yields. cGrignard reagent added as solution in DCM. dPhCO2Ph (39%) was also isolated. eTrace amounts of the ester byproduct PhCO2Ph was isolated.

Based on our previously developed selective tin hydride reduction of monosubstituted pyrazinium salts [9], we expected the Grignard reagent to add regioselectively to give 1,2-dihydropyrazine 3a. DFT calculations support the observations that the isolated regioisomer we obtained was the result of a thermodynamically favored 1,2-addition over a 1,6-addition [9]. It has also been shown that TMS-ketene acetals add selectively to N-triflate pyrazinium salts [12]. 1H NMR analysis confirmed this by showing a rotameric pair of singlets at 3.89 and 3.84 ppm for the methoxy group at C3, a rotameric pair of singlets at 5.89 and 5.58 ppm for the proton at C2 and a rotameric pair of doublets at 6.17, 6.15 ppm and 6.68, 6.63 ppm for the two vinyl protons at C5 and C6, respectively. This result is in agreement with our observation that nucleophiles favored 1,2-addition over a 1,6-addition [9]. A formation of 1,6-dihydropyrazine was not observed.

With THF identified as the optimal solvent to use, we sought to expand the scope of the Grignard addition to various mono- and disubstituted N-acylpyrazinium salts (Figure 1). Phenyl chloroformate was the acylating reagent of choice for this study due to benzyl or methyl chloroformates producing products in very poor yields. A variety of alkyl Grignard reagents were shown to add regioselectively to methoxy-substituted salts to give the dihydropyrazines in yields ranging from 48% to 73% (Figure 1, compounds 3bg). Aryl Grignard reagents containing an electron-withdrawing and donating group proceeded to give the desired substituted products in moderate yields (Figure 1, compounds 3hj). The examination of the Grignard addition to benzyloxy- or p-methoxybenzyloxy (PMB)-substituted pyrazinium salts, resulted in obtaining dihydropyrazines in yields that were comparable to the methoxy salts (Figure 1, compounds 4a,b and 5).

[1860-5397-15-8-1]

Figure 1: Regioselective addition of Grignard reagents to mono- and disubstituted pyrazinium salts (yields refer to isolated yields).

We next subjected disubstituted N-acylpyrazinium salts to this reaction. Based on our results from the monosubstituted substrates, a 1,2-addition of the Grignard was expected to occur. When an aryl group was present on the ring, trisubstituted dihydropyrazines in good yields ranging from 78–100% were produced (Figure 1, compounds 6, 7a,b and 12). An alkyl substitution with either an ethyl or benzyl group on the pyrazinium salts gave an 81% yield for both 10 and 11 (Figure 1). Reacting a Grignard with pyrazinium salts disubstituted with electron-donating alkoxy groups gave us the desired dihydropyrazine in moderate to good yields of 45–88% (Figure 1, compounds 8, 9a,b) while the presence of an electron-withdrawing ester group generated 13 in a yield of 49%.

With the substituted 1,2-dihydropyrazines in hand, we next wanted to demonstrate their usefulness for synthesizing substituted Δ5-2-oxopiperazines. Processes into this structural motif would be very useful due to their presence in a variety of biologically active small molecules and natural products [23-30]. We previously reported that 3-methoxy-1,2-dihydropyrazines can be easily converted to Δ5-2-oxopiperazines using 1 M HCl(aq) in methanol [9]. When we applied these acidic conditions on the phenyl-substituted 3-methoxy-1,2-dihydropyrazine 3a, only a 5% yield of Δ5-2-oxopiperazine 14a was obtained (Table 2, entry 1). This low yield appears to be due to the presence of a ring-opened side product [31]. The yields of the Δ5-2-oxopiperazines were improved to 61% and 92%, respectively, when the reaction was repeated on phenyl-substituted 1,2-dihydropyrazines containing benzyl and p-methoxybenzyl (PMB) ether groups (Table 2, entries 2 and 3). This enhancement in yield can be attributed to the benzyl and PMB groups’ better sensitivity towards removal under acidic conditions [32]. With the aqueous acidic conditions not being suitable for converting 3-methoxy-1,2-dihydropyrazine 3a, we decided to run this reaction under anhydrous acidic conditions. After stirring dihydropyrazine 3a in the presence of HCl/dioxane at 0 °C for 30 min, we were pleased to see that Δ5-2-oxopiperazine 14a was obtained in an excellent yield of 93% (Table 2, entry 4). Subjecting both benzyl and 2-bromobenzyl-substituted dihydropyrazines 3f and 3g to these acidic conditions gave 95% and 88% yields of 14b and 14c, respectively (Table 2, entries 5 and 6). When we examined the use of anhydrous acidic conditions on 4b and 5, quantitative yields of Δ5-2-oxopiperazine 14a were obtained (Table 2, entries 7 and 8). Finally, under these conditions, the trisubstituted dihydropyrazine 7a was easily converted to a disubstituted Δ5-2-oxopiperazine 15a in a yield of 73% (Table 2, entry 9).

Table 2: Conversion of dihydropyrazine to Δ5-2-oxopiperazines under acidic conditions.

[Graphic 2]
entry R R1 R2 acid time (min) product yield (%)a
1 H Me Ph HCl(aq)/MeOH 60 [Graphic 3]
14a
5
2 H Bn Ph HCl(aq)/MeOH 45 14a 61
3 H PMB Ph HCl(aq)/MeOH 60 14a 92
4b H Me Ph HCl/dioxane 30 14a 93
5b H Me Bn HCl/dioxane 30 [Graphic 4]
14b
95
6b H Me 2-BrBn HCl/dioxane 45 [Graphic 5]
14c
85
7b H Bn Ph HCl/dioxane 20 14a 100
8b H PMB Ph HCl/dioxane 10 14a 100
9b p-MeOPh Me Ph HCl/dioxane 45 [Graphic 6]
15a
73

aIsolated yields. b4 M HCl/dioxane was used.

Following the step-wise conversion of 1,2-dihydropyrazines to Δ5-2-oxopiperazines, we decided to develop a one-pot approach towards their synthesis (Table 3). As described above, we first synthesized the phenyl-substituted 1,2-dihydropyrazine 4b by adding a phenyl Grignard reagent to benzyloxy-substituted N-acylpyrazinium salt in THF at −41 °C. Next, 1 M HCl(aq)/MeOH was added and the reaction was monitored by TLC. After 1 h, the hydrolysis of 4b was completed to give 14a in a good yield of 80% (Table 3, entry 1). Disubstituted Δ5-2-oxopiperazines 15bd can be made similarly with yields ranging from 71–80% (Table 3, entries 2–4). This simple approach towards Δ5-2-oxopiperazines provides access into compounds that can be reduced into mono- and disubstituted 2-oxopiperazines [33,34]. This structure is a common scaffold found in natural products and biologically active small molecules [23].

Table 3: One-pot synthesis of substituted Δ5-2-oxopiperazines.

[Graphic 7]
entry R product yield (%)a
1 H [Graphic 8]
14a
80
2 Et [Graphic 9]
15b
80
3 Bn [Graphic 10]
15c
72
4 Ph [Graphic 11]
15d
71

aIsolated yields.

Conclusion

In conclusion, we have demonstrated that various Grignard reagents can be regioselectively added to mono- and disubstituted N-acylpyrazinium salts to give di- and trisubstituted 1,2-dihydropyrazines in moderate to excellent yields. Under acidic conditions, the dihydropyrazines can be easily converted to substituted Δ5-2-oxopiperazines. These compounds can potentially serve as templates for making substituted 2-oxopiperazines. The investigation into the synthetic utility of this reaction is currently underway and will be reported in due course.

Supporting Information

Supporting Information File 1: Experimental section and NMR spectra.
Format: PDF Size: 4.1 MB Download

Acknowledgements

We gratefully acknowledge the financial support from the National Institute of General Medical Sciences (Grant number: SC3GM105572) and the Golden LEAF Foundation, Rocky Mount, NC, for their financial support in setting up the BRITE Institute. HRMS data were obtained at the North Carolina State University Department of Chemistry Mass Spectrometry Facility.

References

  1. Lee, Y. B.; Gong, Y.-D.; Kim, D. J.; Ahn, C.-H.; Kong, J.-Y.; Kang, N.-S. Bioorg. Med. Chem. 2012, 20, 1303–1309. doi:10.1016/j.bmc.2011.12.026
    Return to citation in text: [1]
  2. Chetan, B.; Bunha, M.; Jagrat, M.; Sinha, B. N.; Saiko, P.; Graser, G.; Szekeres, T.; Raman, G.; Rajendran, P.; Moorthy, D.; Basu, A.; Jayaprakash, V. Bioorg. Med. Chem. Lett. 2010, 20, 3906–3910. doi:10.1016/j.bmcl.2010.05.020
    Return to citation in text: [1] [2]
  3. Garg, N. K.; Stoltz, B. M. Tetrahedron Lett. 2005, 46, 2423–2426. doi:10.1016/j.tetlet.2005.02.054
    Return to citation in text: [1] [2] [3]
  4. Guo, C.; Bhandaru, S.; Fuchs, P. L.; Boyd, M. R. J. Am. Chem. Soc. 1996, 118, 10672–10673. doi:10.1021/ja962646q
    Return to citation in text: [1] [2]
  5. Hirsh, A. J.; Molino, B. F.; Zhang, J.; Astakhova, N.; Geiss, W. B.; Sargent, B. J.; Swenson, B. D.; Usyatinsky, A.; Wyle, M. J.; Boucher, R. C.; Smith, R. T.; Zamurs, A.; Johnson, M. R. J. Med. Chem. 2006, 49, 4098–4115. doi:10.1021/jm051134w
    Return to citation in text: [1] [2] [3]
  6. Walker, J. A.; Liu, W.; Wise, D. S.; Drach, J. C.; Townsend, L. B. J. Med. Chem. 1998, 41, 1236–1241. doi:10.1021/jm970532z
    Return to citation in text: [1] [2]
  7. Horton, D. A.; Bourne, G. T.; Smythe, M. L. Chem. Rev. 2003, 103, 893–930. doi:10.1021/cr020033s
    Return to citation in text: [1] [2]
  8. Evans, B. E.; Rittle, K. E.; Bock, M. G.; DiPardo, R. M.; Freidinger, R. M.; Whitter, W. L.; Lundell, G. F.; Veber, D. F.; Anderson, P. S.; Chang, R. S. L.; Lotti, V. J.; Cerino, D. J.; Chen, T. B.; Kling, P. J.; Kunkel, K. A.; Springer, J. P.; Hirshfield, J. J. Med. Chem. 1988, 31, 2235–2246. doi:10.1021/jm00120a002
    Return to citation in text: [1]
  9. Williams, A. L.; St. Hilaire, V. R.; Lee, T. J. Org. Chem. 2012, 77, 4097–4102. doi:10.1021/jo202498r
    Return to citation in text: [1] [2] [3] [4] [5]
  10. Rudler, H.; Denise, B.; Xu, Y.; Parlier, A.; Vaissermann, J. Eur. J. Org. Chem. 2005, 3724–3744. doi:10.1002/ejoc.200500162
    Return to citation in text: [1] [2]
  11. Rudler, H.; Denise, B.; Xu, Y.; Vaissermann, J. Tetrahedron Lett. 2005, 46, 3449–3451. doi:10.1016/j.tetlet.2005.03.131
    Return to citation in text: [1] [2]
  12. Garduño-Alva, A.; Ortega-Alfaro, M. C.; López-Cortés, J. G.; Chávez, I.; Barroso-Flores, J.; Toscano, R. A.; Rudler, H.; Álvarez-Toledano, C. Can. J. Chem. 2012, 90, 469–482. doi:10.1139/v2012-016
    Return to citation in text: [1] [2] [3]
  13. Hiebel, A.-C.; Comins, D. L. Tetrahedron 2015, 71, 7354–7360. doi:10.1016/j.tet.2015.04.086
    Return to citation in text: [1]
  14. Tsukanov, S. V.; Comins, D. L. J. Org. Chem. 2014, 79, 9074–9085. doi:10.1021/jo501415r
    Return to citation in text: [1]
  15. Cash, B. M.; Prevost, N.; Wagner, F. F.; Comins, D. L. J. Org. Chem. 2014, 79, 5740–5745. doi:10.1021/jo500878v
    Return to citation in text: [1]
  16. Wu, Y.; Li, L.; Li, H.; Gao, L.; Xie, H.; Zhang, Z.; Su, Z.; Hu, C.; Song, Z. Org. Lett. 2014, 16, 1880–1883. doi:10.1021/ol500302r
    Return to citation in text: [1]
  17. Sahn, J. J.; Bharathi, P.; Comins, D. L. Tetrahedron Lett. 2012, 53, 1347–1350. doi:10.1016/j.tetlet.2011.12.127
    Return to citation in text: [1]
  18. Gotchev, D. B.; Comins, D. L. J. Org. Chem. 2006, 71, 9393–9402. doi:10.1021/jo061677t
    Return to citation in text: [1]
  19. Kuethe, J. T.; Comins, D. L. J. Org. Chem. 2004, 69, 2863–2866. doi:10.1021/jo049943v
    Return to citation in text: [1]
  20. Comins, D. L.; Williams, A. L. Tetrahedron Lett. 2000, 41, 2839–2842. doi:10.1016/s0040-4039(00)00298-7
    Return to citation in text: [1]
  21. Foks, H. Acta Pol. Pharm. 1978, 35, 525–528.
    Return to citation in text: [1]
  22. Andersson, H.; Banchelin, T. S.-L.; Das, S.; Gustafsson, M.; Olsson, R.; Almqvist, F. Org. Lett. 2010, 12, 284–286. doi:10.1021/ol902619h
    Return to citation in text: [1]
  23. De Risi, C.; Pelà, M.; Pollini, G. P.; Trapella, C.; Zanirato, V. Tetrahedron: Asymmetry 2010, 21, 255–274. doi:10.1016/j.tetasy.2010.02.008
    Return to citation in text: [1] [2]
  24. Vieth, M.; Siegel, M. G.; Higgs, R. E.; Watson, I. A.; Robertson, D. H.; Savin, K. A.; Durst, G. L.; Hipskind, P. A. J. Med. Chem. 2004, 47, 224–232. doi:10.1021/jm030267j
    Return to citation in text: [1]
  25. Kitamura, S.; Fukushi, H.; Miyawaki, T.; Kawamura, M.; Konishi, N.; Terashita, Z.-i.; Naka, T. J. Med. Chem. 2001, 44, 2438–2450. doi:10.1021/jm0004345
    Return to citation in text: [1]
  26. Endo, A.; Yanagisawa, A.; Abe, M.; Tohma, S.; Kan, T.; Fukuyama, T. J. Am. Chem. Soc. 2002, 124, 6552–6554. doi:10.1021/ja026216d
    Return to citation in text: [1]
  27. Mori, K.; Rikimaru, K.; Kan, T.; Fukuyama, T. Org. Lett. 2004, 6, 3095–3097. doi:10.1021/ol048857e
    Return to citation in text: [1]
  28. Lee, S.-C.; Park, S. B. J. Comb. Chem. 2007, 9, 828–835. doi:10.1021/cc0700492
    and references within.
    Return to citation in text: [1]
  29. Candelon, N.; Shinkaruk, S.; Bennetau, B.; Bennetau-Pelissero, C.; Dumartin, M.-L.; Degueil, M.; Babin, P. Tetrahedron 2010, 66, 2463–2469. doi:10.1016/j.tet.2010.01.088
    Return to citation in text: [1]
  30. El Kaïm, L.; Grimaud, L.; Reddy Purumandla, S. J. Org. Chem. 2011, 76, 4728–4733. doi:10.1021/jo200397m
    Return to citation in text: [1]
  31. Major product present was the ring-opened compound 16; see Supporting Information File 1.
    Return to citation in text: [1]
  32. Wuts, P. G. M.; Greene, T. W. Greene's protective groups in organic synthesis, 4th ed.; Wiley-Interscience: Hoboken, NJ, 2007.
    Return to citation in text: [1]
  33. Peng, H.; Carrico, D.; Thai, V.; Blaskovich, M.; Bucher, C.; Pusateri, E. E.; Sebti, S. M.; Hamilton, A. D. Org. Biomol. Chem. 2006, 4, 1768–1784. doi:10.1039/b517572k
    Return to citation in text: [1]
  34. Horwell, D. C.; Lewthwaite, R. A.; Pritchard, M. C.; Ratcliffe, G. S.; Ronald Rubin, J. Tetrahedron 1998, 54, 4591–4606. doi:10.1016/s0040-4020(98)00092-1
    Return to citation in text: [1]
Other Beilstein-Institut Open Science Activities